Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Modified Pittsburgh staging system8,9
| T | assessment |
|---|---|
| T1 | Tumour limited to external auditory canal without bony erosion or evidence of soft tissue involvement |
| T2 | Tumour with limited external auditory canal bone erosion (not full thickness) or limited (<0.5 cm) soft-tissue involvement |
| T3 | Tumour eroding osseous external auditory canal (full thickness) with limited (<0.5 cm) soft tissue involvement or tumour involving the middle ear and/or mastoid |
| T4 | Tumour eroding cochlea, petrous apex, medial wall of the middle ear, carotid canal, jugular foramen or dura, or with extensive soft tissue involvement (>0.5 cm) such as involvement of temporomandibular joint or styloid process, or evidence of facial paresis |
| N | assessment |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis |
| M | assessment |
| M0 | No distant metastasis |
| M1 | Distant metastasis |
| Stage | group |
| I | T1N0M0* |
| II | T2N0M0* |
| III | T3N0M0‡, T1N1M0‡ |
| IV | T4N0M0‡, T2–4N1M0‡, T1–4N0–1M1† |
Dataset of patients with lateral skull-base cancer treated between 2011 and 2019
| Age | Year | Site | ICD-10 | HP | Clinical TNM staging | Preoperative imaging | PTA | Treatment modalities | Otosurgical resection | Parotidectomy | Neck dissection | TMJ resection | Reconstruction | RTC | Survival | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cT | cN | cM | Grade | |||||||||||||||
| 80M | 2012 | aEECR | C44.2 | SCC | cT4* | cN1* | cM0* | IVP | CTSB, USN | yes | SURG➜RT | WLE | partial | iSND | none | PM | R1 | 8.1 |
| 79M | 2014 | EACCR | C44.2 | BCC | cT1P | cN0P | cM0P | IP | CTSB | none | SURG | WLE | none | none | yes | skin graft | R0 | 6.9 |
| 52M | 2014 | EACCL | C44.2 | SCC | cT4P | cN0P | cM0P | IVP | MRISB, CTSB, USN | yes | SURG | LTBR | partial | iSND | none | primary closure | R0 | 5.7 |
| 90F | 2015 | EACCL | C44.2 | SCC | T3P | cN0P | cM0P | IIIP | CTSB, USN | yes | SURG | LTBR | none | none | none | primary closure | R0 | 5.5 |
| 59M | 2017 | EACCL | C44.2 | ACC | cT4P | cN0P | cM0P | IVP | MRISB, CTSB, USN | yes | SURG➜RT | LTBR | partial | iSND | none | primary closure | R1 | 5.2 |
| 50M | 2017 | EACCL | C44.2 | BCC | cT P | cN0P | cM0P | IP | MRISB | none | ECT»SURG | WLE | partial | none | none | primary closure | R0 | 4.5 |
| 85F | 2017 | aEECR | C44.2 | BCC | cT2* | cN0* | cM0* | II* | USN | none | SURG | WLE | none | none | none | primary closure | R0 | (†2.9 88) |
| 75M | 2018 | aEECL | C44.2 | BCC | cT1* | cN0* | cM0* | I* | none | none | SURG | WLE | none | none | none | skin graft | R0 | (†2.8 78) |
| 79M | 2018 | MECR | C30.1 | SCC | cT3P | cN0P | cM0P | IIIP | MRISB, CTSB, MRIN | yes | SURG | LTBR | none | none | none | primary closure | R1 | (†0.4 80) |
| 67M | 2018 | aEECR | C44.2 | BCC | cT4a* | cN0* | cM0* | IVa* | MRISB, CTSB | yes | SURG | LTBR+ | partial | iSND | none | RFFF | R0 | 2.3 |
| 66F | 2019 | EACCL | C44.2 | SCC | cT1P | cN1P | cM0P | IIIP | MRISB, CTSB | yes | SURG | WLE | none | iSND | none | secondary intention | R0 | 2.0 |
| 76M | 2019 | aEECR | C44.2 | SCC | cT3* | cN0* | cM0* | III* | MRISB, CTSB | yes | RT»SURG | LTBR+ | partial | iSND | none | PM | R0 | 2.4 |
| 85M | 2012 | MECR | C30.1 | SCC | cT3P | cN0P | cM0P | IIIP | CTSB, USN | yes | SURG➜RT | LTBR | none | none | none | primary closure | R0 | (†0.5 85) |
| 73F | 2014 | aEECL | C44.2 | BCC | cT4a* | cN0* | cM0* | IVa* | MRISB, CTSB, USN | yes | RT»ECT»SURG | LTBR+ | partial | iSND | none | RFFF | R0 | 1.6 |
| 58F | 2014 | aPCR | C07 | MC | cT4a** | cN0** | cM0** | IVa** | MRISB, CTSB | yes | SURG➜RT»SURG | LTBR+ | performed previously | iSND | none | ALT | R0 | 0.6 |
| 85F | 2015 | aPCR | C07 | AC | cT4a* | cN2b* | cM0* | IVa* | CTSB | yes | SURG➜RT | MWLE | total | iMRND | none | ALT | R0 | 0.3 |
| 84M | 2017 | aEECL | C44.2 | SCC | cT2* | cN0* | cM0* | II* | USN | none | SURG➜RT | WLE | partial | iSND | none | secondary intention | R0 | 0.8 |